Cambridge-based JuliaHub is strengthening its position in the pharmaceutical sector with significant investment in its CFR Part 11-compliant platform, offering integrated solutions for pharmacometrics, modelling and regulatory compliance.
The biotechnology sector marks a significant advancement in genetic medicine with EG 427’s achievement in treating neurogenic bladder using a novel herpes-based vector approach.
In a significant development for radiopharmaceutical advancement, isotope technology provider Eckert & Ziegler has established a comprehensive partnership with Bicycle Therapeutics to supply radioisotopes and manufacture novel bicyclic peptide-based radiopharmaceuticals for upcoming clinical trials.
Seth Benson joins the executive team at Nuclera as Chief Financial Officer, bringing extensive life sciences financial expertise to drive the company’s global commercial expansion of its eProtein Discovery system following a $75 million financing round
Celonic Group, a dedicated biologics contract development and manufacturing organisation (CDMO), has finalised a multi-year commercial manufacturing agreement with LINDIS Biotech for catumaxomab production. The announcement, made on 19 February 2025, establishes Celonic’s Heidelberg facility as the manufacturing hub for this first-in-class therapeutic antibody.
Sphere Fluidics, a pioneer in droplet-based microfluidics technology, has announced its comprehensive rebranding to Sphere Bio. The name change, revealed on 25th February 2025, signifies the company’s strategic pivot and commercial growth trajectory as it continues to expand its footprint in the single-cell analysis market.
Discover the perfect solution for every laboratory size. Due to its compact design respons®240c is ideal for small labs that require an analyzer capable of a constant throughput of 240 tests/hour along with intuitively operated software. Advanced features like onboard hemolysis and a grated photometer with 12 wavelengths ensure precision and efficiency.
A new sterile bead-based plating method offers enhanced efficiency and safety for microbiological work, potentially improving laboratory throughput and reproducibility.
Cambridge-based organ-on-chip technology company CN Bio has introduced a new in vitro assay kit designed to assess human oral drug bioavailability. The PhysioMimix Bioavailability assay kit: Human 18 enables pharmaceutical researchers to generate predictive human data earlier in the drug development pipeline, reducing reliance on animal studies.
Cambridge-based Enhanc3D Genomics has unveiled an integrated suite of multi-omics solutions designed to enhance drug discovery processes. The platform, which leverages proprietary Promoter Capture Hi-C technology, enables high-resolution mapping of genomewide regulatory interactions to support more targeted therapeutic development approaches.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.